Mounjaro (tirzepatide)

Mounjaro (tirzepatide) is a prescription medicine indicated in combination with diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

In the EU, Mounjaro (tirzepatide) is also approved for use alongside diet and exercise to help people lose weight or keep their weight under control. In this capacity, it is intended for patients with BMI >30 or BMI >27, if weight-related health conditions such as diabetes, high blood pressure, or obstructive sleep apnoea are present

What is Mounjaro (tirzepatide) for?

Mounjaro (tirzepatide) is indicated for the treatment of:

• Patients with type 2 diabetes mellitus, alongside diet and exercise;
• In the EU: Patients with BMI >30 or BMI >27, if weight-related health conditions such as diabetes, high blood pressure, or obstructive sleep apnoea are present.

How does Mounjaro (tirzepatide) work?

Tirzepatide, the active ingredient in Mounjaro, mimics the effects of two natural gut hormones: GLP-1 and GIP. These hormones interact with receptors in areas like the pancreas and brain, prompting the pancreas to release more insulin after meals and helping to lower blood sugar levels in people with type 2 diabetes. By acting on these same pathways, tirzepatide also helps curb appetite and supports weight management.

Where has Mounjaro (tirzepatide) been approved?

Mounjaro (tirzepatide) is approved in multiple countries, though indications may vary. For example, the FDA in the USA has only approved Mounjaro for use in patients with type 2 diabetes . In the EU, Mounjaro is also approved for use in weight management and weight loss .

In addition to the USA and the EU, Mounjaro (tirzepatide) is also approved in Canada, UK, Australia, Japan, Switzerland, India, China, and South Africa.